Brief: Calliditas Announces Positive Transform Phase 2B Topline Data
26/07/2024 07:09
July 26 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* CALLIDITAS ANNOUNCES POSITIVE TRANSFORM PHASE 2B TOPLINE
DATA IN
PRIMARY BILIARY CHOLANGITIS
* PHASE 2B TRIAL MET ITS PRIMARY ENDPOINT, SHOWING
STATISTICALLY
SIGNIFICANT IMPROVEMENT IN ALP FOR BOTH DOSES TESTED VERSUS
PLACEBO
Source text for Eikon: ID:nWkr53r5v
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations